Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (19417)	3/22/2006 2:21:10 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks Bernard. I doubt if the Plavix settlement has any bearing on Orencia patent dispute at all. Peter

To: Jibacoa who wrote (19417)	3/22/2006 4:27:51 PM
From: Doc Bones	Read Replies (2) \| Respond to of 52153

If the stock can close above the resistance at $3.75 it may be an early indication that there could be a deal in the works with BMY. My experience with IGEN tells me that "potential settlement" stocks can go up and down many times on spec before the settlement comes. Of course if there is a good settlement, it will likely be preceded by this kind of strong move, information sieves being what they are. Also, professional traders learn cynicism in the school of hard knocks, and so Wall Street may undervalue possible future deals. "Oh they tell me of a pie up in the sky / Waiting for me when I die." - Jimmy Cliff 'The Harder They Come.' RGEN peaked at 5 in Feb. finance.yahoo.com Doc